RESEARCH · BPC-157 · TB-500
BPC-157 and TB-500: Preclinical Tendon and Cell Studies, and Why Human Data Are Almost Absent
PurixLab’s BPC-157 + TB-500 10mg is a lyophilized research vial labelled with equal amounts of the two compounds: 5mg BPC-157 and 5mg TB-500. Our earlier posts cover what is in the blend and the three-component GLOW BLEND. This article goes deeper into the published literature on the two peptides, and especially into how little of it involves people.
BPC-157: rat tendon studies and cell work
BPC-157 is a stable gastric pentadecapeptide with the sequence GEPPPGKPADDAGLV. In the 2003 rat Achilles-transection study, the authors reported that it improved biomechanical, functional and microscopic outcomes compared with controls, and in cultured tendon cells it opposed the growth-inhibiting effect of 4-hydroxynonenal [1]. A 2006 rat tendon-to-bone study reported improved healing and reduced aggravation by the corticosteroid 6α-methylprednisolone [2]. At the cell level, BPC-157 accelerated outgrowth of tendon fibroblasts from explants, increased cell survival under hydrogen-peroxide stress and increased fibroblast migration, with phosphorylation of FAK and paxillin [3].
These are animal and cell findings. A 2019 review noted that most studies used small rodent models, that efficacy is yet to be confirmed in humans, and that only a handful of research groups have studied the peptide in depth [4].
The pharmaceutical gap
A 2026 narrative review describes BPC-157 as pharmaceutically underdeveloped: no approved formulation, no validated dosing regimen and no completed phase II trial. It reports a plasma half-life under 30 minutes in a preclinical study, which contrasts with biological effects lasting hours to days, and concludes that the main barrier is the absence of characterised formulations and validated pharmacokinetics rather than a lack of biological activity [5].
The human data: three small pilot reports
- A retrospective chart review of 17 patients with knee pain, 16 of whom were reached by phone; the authors state that no specific tools were used to measure function [6].
- An uncontrolled pilot in 12 women with interstitial cystitis, using material from a compounding pharmacy and a self-reported response questionnaire; no adverse events were reported [7].
- A pilot of two participants that measured heart, liver, kidney, thyroid and glucose biomarkers and reported no measurable effects [8].
A 2025 review counted only these three pilot studies and called BPC-157 investigational, with rigorous large-scale trials lacking [9]. A systematic review of 36 studies found 35 preclinical and one clinical study [10]. In short, the human evidence is uncontrolled, tiny and unreplicated.
TB-500 is not thymosin β4
Thymosin β4 is a naturally occurring peptide released by platelets and macrophages after injury [11]. TB-500, however, was identified analytically as the N-terminally acetylated 17–23 fragment, Ac-LKKTETQ [12]; a doping-control laboratory describes it as a veterinary preparation of that fragment [13]. Note that the 2026 rat tendon study describes TB-500 as “synthetic thymosin beta-4” [14], so labelling in the literature is not consistent. Full-length thymosin β4 findings cannot be assumed to carry over to a seven-residue fragment.
The full-length literature is itself contested. One mouse study found thymosin β4 essential for coronary vessel development and able to stimulate outgrowth from adult epicardial explants [15]. Knockout mice, however, had normal heart and vessel formation and unchanged adult cardiac function, and the authors concluded thymosin β4 is dispensable for these processes [16], a conclusion they repeated for vascular development, noting it conflicts with another group’s results [17]. In humans, a small phase 2 trial of thymosin β4 eye drops (nine patients with severe dry eye) reported symptom and sign improvements [18]; that is full-length peptide in an ophthalmic formulation, not TB-500.
The only combination study
In the 2026 rat Achilles study, TB-500 showed a significant biomechanical advantage at four weeks and TB-500 and the combination group had significantly lower Movin tendon-histology scores than controls, but combining BPC-157 with TB-500 did not confer additional benefit over either agent alone; the authors call it exploratory [14].
What remains unknown
- Human efficacy, safety and pharmacokinetics under controlled conditions [9,5].
- Independent replication of the rodent literature [4].
- Whether thymosin β4 results apply to TB-500, and the role of thymosin β4 itself given conflicting knockout data [12,16,17].
- Any benefit of the combination [14]. A 2026 review of unapproved peptides also concluded that rigorous human safety data are scarce, with potential for serious harm [19].
General laboratory storage background
Laboratories should always follow the product label, any batch documentation and their own approved procedures. As general background, peptide suppliers’ technical guides describe broadly similar practice for lyophilized (freeze-dried) peptides:
- Keep it dry, dark and cold. Lyophilized peptides should be kept away from heat, light and moisture; for longer-term storage, guides commonly recommend about −20 °C [20,21].
- Avoid condensation. Let a cold vial reach room temperature, ideally in a desiccator, before opening, then reseal promptly [21].
- Limit freeze–thaw cycles. Aliquoting by planned experiment reduces freeze–thaw cycles and air exposure [20].
- Solutions are short-lived. Peptides in solution have a much shorter shelf life than the dry powder [20,21].
This is general laboratory information, not a protocol, and it contains no instructions for human use.
BPC-157 + TB-500 10mg at PurixLab
BPC-157 + TB-500 10mg: a labelled lyophilized research vial (BPC-157 5mg + TB-500 5mg, 10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Codes: WELCOME10 takes 10% off eligible orders below C$400; PURIX20 takes 20% off eligible orders of C$400 or more before discount and tax. One offer per order; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PubMed 14554208 · doi:10.1016/S0736-0266(03)00110-4
- Krivic A, Anic T, Seiwerth S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-9. PubMed 16583442 · doi:10.1002/jor.20096
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672 · doi:10.1152/japplphysiol.00945.2010
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PubMed 30915550 · doi:10.1007/s00441-019-03016-8
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. PubMed 42198317 · PMC13210877 · doi:10.3390/pharmaceutics18050625
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PubMed 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PubMed 39325560
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PubMed 40131143
- McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PubMed 40789979 · PMC12446177 · doi:10.1007/s12178-025-09990-7
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed 40756949 · PMC12313605 · doi:10.1177/15563316251355551
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294 · doi:10.1517/14712598.2012.634793
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926 · doi:10.52312/jdrs.2026.2951
- Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-82. PubMed 17108969 · doi:10.1038/nature05383
- Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456-64. PubMed 22158707 · PMC3739283 · doi:10.1161/CIRCRESAHA.111.258616
- Banerjee I, Moore Morris T, Evans SM, et al. Thymosin β4 is not required for embryonic viability or vascular development. Circ Res. 2013;112(3):e25-8. PubMed 23371905 · PMC3712119 · doi:10.1161/CIRCRESAHA.111.300197
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. PubMed 25826322 · doi:10.1097/ICO.0000000000000379
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639 · doi:10.1007/s40279-026-02437-0
- GenScript. Peptide Storage and Handling Guidelines (technical resource). GenScript
- AAPPTec. Handling and Storage of Peptides — FAQ (technical resource). AAPPTec